

From *TreatmentUpdate* 226

A clinical trial of friendly yeast

In low- and middle-income countries, clinical trials of the friendly microbe *S. boulardii* (a yeast) have found that it can generally reduce diarrhea.

Researchers in Barcelona, Spain, conducted a randomized, double-blind, placebo-controlled trial with 44 HIV-positive people taking HIV treatment (ART). Participants took supplements of *S. boulardii* for 12 weeks. Most participants who received *S. boulardii* had reduced levels of bacterial proteins in their blood. Levels of the immunological signal IL-6 (interleukin-6), which is associated with inflammation, decreased modestly. These changes persisted for at least three months after the cessation of the study.

Study details

All participants had been taking ART and had a viral load of less than 20 copies/mL for at least two years prior to entering the present study. Researchers reported that half of the participants entered the study with more than 400 CD4+ cells/mm³.

Participants took about 5 billion units of *S. boulardii* daily. This probiotic was taken in capsules three times daily.

Key findings

The use of *S. boulardii* was associated with the following changes compared to placebo:

- a decrease in IL-6 levels in the blood
- a decrease in levels of bacterial proteins in the blood
- a decrease in activation of the immune system (this was shown as a decrease in the level of a protein called beta2-microglobulin in the blood)

These changes were statistically significant.

There were no other notable and significant changes in the study, including CD4+ and CD8+ cell counts.

The researchers found that the friendly yeast was well tolerated and did not cause harm.

Bear in mind

Supplements of *S. boulardii* were used in the time before ART was available to try to reduce the severity of AIDS-related diarrhea.

In the current era when ART is widely available in high-income countries, perhaps *S. boulardii* supplements may have another use, such as reducing inflammation in the immune system. However, note that the present study was relatively small and adherence to a thrice-daily regimen of probiotics was not directly measured. Despite this, the overall design of the Barcelona study suggests that there is modest benefit. The researchers said that a longer study may be useful with this probiotic.

—Sean R. Hosein

REFERENCES:

1. Villar-García J, Hernández JJ, Güerri-Fernández R, et al. Effect of probiotics (*Saccharomyces boulardii*) on microbial translocation and inflammation in HIV-treated patients: a double-blind, randomized, placebo-controlled trial. *Journal of Acquired Immune Deficiency Syndromes* . 2015 Mar 1;68(3):256-263.

2. Villar-García J, Güerri-Fernández R, Moya A, et al. Impact of probiotic *Saccharomyces boulardii* on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial. *PLoS One*. 2017 Apr 7;12(4):e0173802.

Produced By:



Canada's source for
HIV and hepatitis C
information

555 Richmond Street West, Suite 505, Box 1104
Toronto, Ontario M5V 3B1 Canada
Phone: 416.203.7122
Toll-free: 1.800.263.1638
Fax: 416.203.8284
www.catie.ca
Charitable registration number: 13225 8740 RR

Disclaimer

Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner knowledgeable about HIV- and hepatitis C-related illness and the treatments in question.

CATIE provides information resources to help people living with HIV and/or hepatitis C who wish to manage their own health care in partnership with their care providers. Information accessed through or published or provided by CATIE, however, is not to be considered medical advice. We do not recommend or advocate particular treatments and we urge users to consult as broad a range of sources as possible. We strongly urge users to consult with a qualified medical practitioner prior to undertaking any decision, use or action of a medical nature.

CATIE endeavours to provide the most up-to-date and accurate information at the time of publication. However, information changes and users are encouraged to ensure they have the most current information. Users relying solely on this information do so entirely at their own risk. Neither CATIE nor any of its partners or funders, nor any of their employees, directors, officers or volunteers may be held liable for damages of any kind that may result from the use or misuse of any such information. Any opinions expressed herein or in any article or publication accessed or published or provided by CATIE may not reflect the policies or opinions of CATIE or any partners or funders.

Information on safer drug use is presented as a public health service to help people make healthier choices to reduce the spread of HIV, viral hepatitis and other infections. It is not intended to encourage or promote the use or possession of illegal drugs.

Permission to Reproduce

This document is copyrighted. It may be reprinted and distributed in its entirety for non-commercial purposes without prior permission, but permission must be obtained to edit its content. The following credit must appear on any reprint: *This information was provided by CATIE (the Canadian AIDS Treatment Information Exchange). For more information, contact CATIE at 1.800.263.1638.*

© CATIE

Production of this content has been made possible through a financial contribution from the Public Health Agency of Canada.

Available online at:
<https://www.catie.ca/en/treatmentupdate/treatmentupdate-226/inflammation/clinical-trial-friendly-yeast>